Oral Presentations
Abstract and Session No.
Title
Presentation Date/Time
(Session 906)
Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
Saturday, December 7, 2024:
10:00 AM PDT
(Session 616)
Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
Saturday, December 7, 2024: 2:30 PM PDT
(Session 616)
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Saturday, December 7, 2024: 2:45 PM
(Session 623)
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
Saturday, December 7, 2024:
2:45 PM PDT
(Session 653)
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Saturday, December 7, 2024:
2:45 PM PDT
(Session 613)
Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
Saturday, December 7, 2024: 4:00 PM PDT
(Session 613)
Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
Saturday, December 7, 2024:
5:00 PM PDT
(Session 623)
Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
Saturday, December 7, 2024:
5:00 PM PDT
(Session 626)
Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
Sunday, December 8, 2024:
9:30 AM PDT
(Session 626)
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Sunday, December 8, 2024:
9:45 AM PDT
(Session 626)
Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
Sunday, December 8, 2024:
10:30 AM PDT
(Session 906)
Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
Sunday, December 8, 2024:
10:00 AM PDT
Abstract 567 (Session 624)
Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
Sunday, December 8, 2024: 12:30 PM PDT
Abstract 570 (Session 624)
Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
Sunday, December 8, 2024: 1:15 PM PDT
(Session 626)
Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
Sunday, December 8, 2024:
12:00 PM PDT
(Session 626)
Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
Sunday, December 8, 2024:
12:30 PM PDT
(Session 626)
The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
Sunday, December 8, 2024:
5:15 PM PDT
(Session 627)
Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
Monday, December 9, 2024:
3:00 PM PDT
(Session 627)
Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
Monday, December 9, 2024:
3:30 PM PDT
(Session 503)
Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
Monday, December 9, 2024: 4:30 PM PDT
(Session 622)
Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
Monday, December 9, 2024:
4:30 PM PDT
Poster Presentations
Abstract and Session No.
Title
Presentation Date/Time
(Session 622)
Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
Saturday, December 7, 2024:
5:30 PM PDT
(Session 623)
Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
Saturday, December 7, 2024:
5:30 PM PDT
(Session 623)
Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
Saturday, December 7, 2024:
5:30 PM PDT
(Session 623)
Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
Saturday, December 7, 2024: 5:30 PM
(Session 624)
Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
Saturday, December 7, 2024:
5:30 PM PDT
(Session 627)
Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
Saturday, December 7, 2024:
5:30 PM PDT
(Session 642)
Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
Saturday, December 7, 2024:
5:30 PM PDT
(Session 905)
Predictors of in-Hospital Mortality in Thrombotic Thrombocytopenic Purpura in Adults in the United States: A Population Analysis Using the NIS Database
Saturday, December 7, 2024: 5:30 PM
(Session 907)
Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients
Saturday, December 7, 2024:
5:30 PM PDT
(Session 907)
Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
Saturday, December 7, 2024:
5:30 PM PDT
(Session 114)
The Impact of Vaccination on COVID-19 Infections and Hospitalizations in Individuals with Sickle Cell Disease
Sunday, December 8, 2024:
6:00 PM PDT
(Session 626)
Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sunday, December 8, 2024:
6:00 PM PDT
(Session 627)
Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Sunday, December 8, 2024:
6:00 PM PDT
(Session 627)
Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
Sunday, December 8, 2024:
6:00 PM PDT
(Session 627)
Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma – Crescendo
Sunday, December 8, 2024:
6:00 PM PDT
(Session 628)
ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
Sunday, December 8, 2024: 6:00 PM
(Session 642)
A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
Sunday, December 8, 2024:
6:00 PM PDT
(Session 654)
Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
Sunday, December 8, 2024:
6:00 PM PDT
(Session 902)
Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States
Sunday, December 8, 2024:
6:00 PM PDT
(Session 902)
Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
Sunday, December 8, 2024:
6:00 PM PDT
(Session 904)
Qualitative Interview Study to Characterize the Treatment Experiences of Participants with Sickle Cell Disease and Assess Perceptions of Red Blood Cell Transfusions
Sunday, December 8, 2024:
6:00 PM PDT
(Session 906)
Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
Sunday, December 8, 2024:
6:00 PM PDT
(Session 906)
Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
Sunday, December 8, 2024:
6:00 PM PDT
(Session 906)
Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
Sunday, December 8, 2024: 6:00 PM PDT
(Session 907)
Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Sunday, December 8, 2024:
6:00 PM PDT
(Session 623)
Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
Monday, December 9, 2024:
6:00 PM PDT
(Session 623)
Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
Monday, December 9, 2024:
6:00 PM PDT
(Session 623)
A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
Monday, December 9, 2024:
6:00 PM PDT
(Session 624)
Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
Monday, December 9, 2024:
6:00 PM PDT
(Session 624)
Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Monday, December 9, 2024: 6:00 PM PDT
(Session 627)
Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
Monday, December 9, 2024:
6:00 PM PDT
(Session 642)
Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study
Monday, December 9, 2024:
6:00 PM PDT
(Session 653)
An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Monday, December 9, 2024:
6:00 PM PDT
(Session 902)
Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective
Monday, December 9, 2024:
6:00 PM PDT
(Session 902)
Cost-Offset Analysis Performed Utilizing Covalent Bruton’s Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia
Monday, December 9, 2024:
6:00 PM PDT
(Session 902)
Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
Monday, December 9, 2024; 6:00 PM PDT
(Session 906)
Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
Monday, December 9, 2024:
6:00 PM PDT
(Session 906)
Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States
Monday, December 9, 2024:
6:00 PM PDT
(Session 907)
Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
Monday, December 9, 2024:
6:00 PM PDT
Program: Special-Interest Sessions
N/A
Training Program Directors Workshop
Friday, December 6, 2024, 9:00 AM-12:00 PM PDT
Program: Oral Symposia
Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL
Sunday, December 8, 2024: 12:00 PM-1:30 PM PDT
Program: Friday Satellite Symposia
N/A
Complex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies
Friday, December 6, 2024: 3:00 PM-6:00 PM PDT
N/A
Emerging insights in biology and treatment approaches to Peripheral T cell Lymphomas
Friday, December 6, 2024: 11:00 AM-2:00 PM PDT
Program: Scientific Workshop
N/A
Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
Friday, December 6, 2024: 2:00 PM- 5:00 PM PDT
N/A
Targeting Novel Metabolic Vulnerabilities in T-Cell Leukemia
Friday, December 6, 2024: 4:17 PM-4:58 PM PDT